Fetal Hemoglobin Induction by Epigenetic Drugs

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Fetal hemoglobin (HbF) counteracts sickle cell disease pathophysiology by inhibiting sickle hemoglobin polymerization.
• High HbF levels confer natural protection against sickle cell complications.
• Hydroxyurea, a cytotoxic drug, was approved to treat sickle cell disease by increasing HbF during bone marrow recovery.

Purpose of the Study:

• To explore non-cytotoxic, epigenetic strategies for increasing fetal hemoglobin (HbF) to treat sickle cell disease.
• To identify specific epigenetic enzymes that repress fetal hemoglobin (HBG) gene expression.

Main Methods:

• Investigated the role of chromatin remodeling in HbF induction.
• Identified key epigenetic enzymes including DNA methyltransferase 1, histone deacetylases, and others that repress HBG.
• Reviewed clinical data on non-cytotoxic HbF induction therapies.

Main Results:

• Epigenetic mechanisms, specifically chromatin remodeling, are involved in HbF induction.
• Inhibition of specific epigenetic enzymes (DNMT1, HDACs, LSD1, PRMT5, EHMT2, CHD4) can repress HBG.
• Clinical studies show non-cytotoxic approaches can significantly increase HbF and total hemoglobin.

Conclusions:

• Directly inhibiting epigenetic repressors of the HBG gene presents a viable, non-cytotoxic therapeutic strategy for sickle cell disease.
• This approach holds potential for developing safe, potent, and disease-modifying therapies.
• Focusing on molecular-targeted, accessible, and cost-effective treatments can achieve worldwide impact for sickle cell patients.